ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 923,67
1,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. YS Biopharma Company Ltd (YS)

  7. YS Biopharma Company Ltd (YS) Actualités

YS

YS Biopharma (YS)

YS Biopharma Company Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:YS
DateHeureSourceTitreSymboleSociété
24/05/202413h30PR Newswire (US)YS Biopharma Announces Name Change to LakeShore BiopharmaNASDAQ:YSYS Biopharma Company Ltd
21/05/202422h15PR Newswire (US)YS Biopharma Announces Results of Extraordinary General MeetingNASDAQ:YSYS Biopharma Company Ltd
07/05/202422h20PR Newswire (US)YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerNASDAQ:YSYS Biopharma Company Ltd
29/04/202414h00PR Newswire (US)YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleNASDAQ:YSYS Biopharma Company Ltd
19/04/202413h00PR Newswire (US)YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024NASDAQ:YSYS Biopharma Company Ltd
18/04/202414h00PR Newswire (US)YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineNASDAQ:YSYS Biopharma Company Ltd
16/04/202414h00PR Newswire (US)YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024NASDAQ:YSYS Biopharma Company Ltd
09/04/202414h00PR Newswire (US)YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineNASDAQ:YSYS Biopharma Company Ltd
03/04/202414h00PR Newswire (US)YS Biopharma Announces Full Repayment of US$40,000,000 Loan FacilityNASDAQ:YSYS Biopharma Company Ltd
05/03/202414h00PR Newswire (US)YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesNASDAQ:YSYS Biopharma Company Ltd
22/02/202423h00PR Newswire (US)YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024NASDAQ:YSYS Biopharma Company Ltd
18/02/202410h30PR Newswire (US)/C O R R E C T I O N -- YS Biopharma Co., Ltd./NASDAQ:YSYS Biopharma Company Ltd
17/02/202402h20PR Newswire (US)YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingNASDAQ:YSYS Biopharma Company Ltd
14/02/202414h00PR Newswire (US)YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate GovernanceNASDAQ:YSYS Biopharma Company Ltd
14/02/202413h50PR Newswire (US)YS Biopharma Announces Appointment of New DirectorsNASDAQ:YSYS Biopharma Company Ltd
12/02/202414h50PR Newswire (US)YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.NASDAQ:YSYS Biopharma Company Ltd
09/02/202412h30PR Newswire (US)YS Biopharma Announces US$40 Million Private Placement FinancingNASDAQ:YSYS Biopharma Company Ltd
09/02/202400h10PR Newswire (US)Shareholders of YS Biopharma Announce an Extraordinary General MeetingNASDAQ:YSYS Biopharma Company Ltd
22/01/202423h00PR Newswire (US)YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024NASDAQ:YSYS Biopharma Company Ltd
08/01/202414h00PR Newswire (US)YS Biopharma Announces Changes to its Board CommitteesNASDAQ:YSYS Biopharma Company Ltd
20/12/202322h30PR Newswire (US)YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General MeetingNASDAQ:YSYS Biopharma Company Ltd
20/12/202314h56PR Newswire (US)YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023NASDAQ:YSYS Biopharma Company Ltd
14/11/202314h30PR Newswire (US)Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price TargetNASDAQ:YSYS Biopharma Company Ltd
31/10/202313h30PR Newswire (US)YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccineNASDAQ:YSYS Biopharma Company Ltd
26/10/202314h30PR Newswire (US)YS Biopharma Announces Receipt of Nasdaq NoticeNASDAQ:YSYS Biopharma Company Ltd
26/09/202314h30PR Newswire (US)YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccineNASDAQ:YSYS Biopharma Company Ltd
15/09/202314h30PR Newswire (US)YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus InfectionNASDAQ:YSYS Biopharma Company Ltd
05/09/202314h30PR Newswire (US)YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma ConferenceNASDAQ:YSYS Biopharma Company Ltd
24/08/202322h15PR Newswire (US)YS Biopharma Announces Purchase of Shares by Company OfficersNASDAQ:YSYS Biopharma Company Ltd
15/08/202323h00PR Newswire (US)YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024NASDAQ:YSYS Biopharma Company Ltd
 Showing the most relevant articles for your search:NASDAQ:YS

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
EU
ACA
Credit Agricole
SPI
SP500
S&P 500
COIN
BTCUSD
Bitcoin
EU
MC
Lvmh Moet Hennessy Louis...
EU
ORA
Orange
USI
USTECH100
US Tech 100
NASDAQ
MSFT
Microsoft
EU
DG
Vinci
EU
CAP
Capgemini
EU
LR
Legrand
NYSE
MRK
Merck
EU
AF
Air FranceKLM
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés